Vernalis has a number of potentially high-value drug development programmes in partnership at present. These include three candidates in oncology and an additional one in asthma and allergic rhinitis.
Current partnered programmes are as follows:
|CPI-444||Cancer||Corvus||Phase I/Ib data (undisclosed)|
|S55746 (Servier 1)||Cancer||Servier / Novartis||Phase I data (undisclosed)|
|CHR-2797 (Tosedostat)||Cancer||CTI BioPharma||Phase II Results|
|RPL554||Asthma, allergic rhinitis||Verona Pharma||Progress to nebulised delivery to treat severe COPD|
|V2006 (Vipadenant)||Cancer||Redox Therapies||Partner Newsflow (undisclosed)|